Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.73 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.71 |
| ▸ | LDLR | P01130 | 2/20 | 0.70 |
| ▸ | KIT | P10721 | 2/20 | 0.70 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.70 |
| ▸ | ABL1 | P00519 | 8/20 | 0.67 |
| ▸ | BCR | P11274 | 7/20 | 0.67 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | RAF1 | P04049 | 1/20 | 0.63 |
| ▸ | HCK | P08631 | 1/20 | 0.62 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493483 | 1.00 | NR2E1 (0.73) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL13659898 | 0.91 | NR2E1 (0.77) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL15442255 | 0.90 | NR2E1 (0.71) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL27143130 | 0.89 | NR2E1 (0.71) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL24532047 | 0.88 | NR2E1 (0.73) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL4254144 | 0.88 | NR2E1 (0.73) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL21612152 | 0.88 | CSF1R (0.71) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL3433139 | 0.88 | NR2E1 (0.60) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL22529506 | 0.88 | EPHB2 (0.55) | NR2E1EPHB2LDLRKITPCSK9 | |
| SCHEMBL22065195 | 0.87 | EPHB2 (0.75) | NR2E1EPHB2LDLRKITPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3795571-B1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2024-05-08 | — | — | EP | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022225972-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2012000304-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | 中国科学院广州生物医药与健康研究院 (CN) | 2012-01-05 | — | — | WO | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-2023933-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133560-A9 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1940843-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007133560-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007021937-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | NR2E1 1890/4885EPHB2 3153/4885LDLR 925/4885 |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | NR2E1 1246/4885EPHB2 1795/4885LDLR 2571/4885 |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | NR2E1 134/4885EPHB2 1745/4885LDLR 469/4885 |
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | NR2E1 1203/4885EPHB2 3171/4885LDLR 616/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | NR2E1 1806/4885EPHB2 2196/4885LDLR 2338/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | NR2E1 2434/4885EPHB2 3120/4885LDLR 4080/4885 |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | ALK, BRAF, DSTYK | NR2E1 2156/4885EPHB2 3739/4885LDLR 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.